Association between paraoxonase 1 (PON1) enzyme activity, PON1 C(−107)T polymorphism, nutritional status, and lipid profile in children

Nutrire - 2016
Gabriela Uliano1, Ludmila Correa Muniz1, Carlos Castilho Barros1, Augusto Schneider1, Sandra Costa Valle1,2
1Department of Nutrition, Universidade Federal de Pelotas, Pelotas, Brazil
2Food for Health Science Centre, Lund University, Lund, Sweden

Tóm tắt

Abstract Background Paraoxonase 1 (PON1) is an enzyme that possesses anti-atherogenic and anti-inflammatory properties with serum levels determined by genetic and exogenous factors. Lower serum PON1 arylesterase activity is associated to metabolic alterations related to childhood overweight and onset and/or development of diabetes and CVD later in life. However, data on the relationship between genetic PON1 polymorphisms and nutritional status as well as lipid profile in children are limited. To investigate the distribution of the C(−107)T PON1 gene polymorphism and its relation with serum PON1 enzyme activity, nutritional status and lipid profile in children. Methods A cross-sectional study was performed including 73 children aged 5 to 7 years who attended public pediatric clinics. PON1 C(−107)T, arylesterase activity, body mass index for the age, and serum lipid profile were evaluated. Results PON1 activity was higher in overweight children compared to the normal weight ones (p = 0.02). The genotypic frequency did not differ between the two groups (p > 0.05). Carriers of CC genotype had higher enzyme activity than T allele carriers, and this difference was greater among normal weight children. HDL levels were higher among normal weight children carrying CC genotype, compared to those carrying the T allele (p < 0.01). Conclusion The PON1 C(−107)T polymorphism is associated with higher serum enzyme activity in children, as observed previously in adults. In addition, this polymorphism also shows association to higher high density lipoprotein (HDL) levels and serum PON1 arylesterase activity in the normal weight children studied.

Từ khóa


Tài liệu tham khảo

Sahebkar, A., Hernández-Aguilera, A., Abelló, D., Sancho, E., Camps, J., Joven, J. Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status. Metabolism-Clinical and Experimental 65, 609–622, 2016. DOI: http://dx.doi.org/10.1016/j.metabol.2016.01.002

Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473–80.

Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, et al. Low paraoxonase activity predicts coronary events in the caerphilly prospective study. Circulation. 2003;107:2775–9.

Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996;33:498–507.

Ferre N, Feliu A, Garcia-Heredia A, Marsillach J, Paris N, et al. Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. Clin Biochem. 2013;46:1830–6.

Deakin S, Leviev I, Brulhart-Meynet MC, James RW. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem J. 2003;372:643–9.

Schrader C, Rimbach G. Determinants of paraoxonase 1 status: genes, drugs and nutrition. Curr Med Chem. 2011;18:5624–43.

Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, et al. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet. 2001;68:1428–36.

Huen K, Harley K, Bradman A, Eskenazi B, Holland N. Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes. Toxicol Appl Pharmacol. 2010;244:181–9.

Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005;69:541–50.

Sociedade Brasileira de Pediatria - SBP. Departamento Científico de Nutrologia. Obesidade na infância e adolescência – Manual de Orientação. 2ª Ed, pp 142, 2012.

Koncsos P, Seres I, Harangi M, Illyes I, Jozsa L, et al. Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels. Pediatr Res. 2010;67:309–13.

Najafi M, Gohari LH, Firoozrai M. Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb Res. 2009;123:503–10.

Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Castaldo M, et al. The paraoxonase promoter polymorphism (−107)T>C is not associated with carotid intima-media thickness in Sicilian hypercholesterolemic patients. Clin Biochem. 2004;37:388–94.

WHO. Organization WH Anthro plus for personal computers: software for assessing growth and development of the world's children. Geneva: WHO; 2007.

Cardiologia SBd, Metabologia SBdEe. I Diretriz de Prevenção da Aterosclerose na Infância e na Adolescência. Arq Bras Cardiol. 2005;85:3–36.

Sumegova K, Nagyova Z, Waczulikova I, Zitnanova I, Durackova Z. Activity of paraoxonase 1 and lipid profile in healthy children. Physiol Res. 2007;56:351–7.

Cayir Y, Cayir A, Turan MI, Kurt N, Kara M, et al. Antioxidant status in blood of obese children: the relation between trace elements, paraoxonase, and arylesterase values. Biol Trace Elem Res. 160, 155–160, 2014

Huen K, Harley K, Brooks J, Hubbard A, Bradman A, et al. Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms. Environ Health Perspect. 2009;117:1632–8.

Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis. 2000;150:295–8.

Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:78–88.

Huen K, Yousefi P, Street K, Eskenazi B, Holland N. PON1 as a model for integration of genetic, epigenetic, and expression data on candidate susceptibility genes. Environ Epigenetics. 2015;1:1–11.

Huen K, Harley K, Beckman K, Eskenazi B, Holland N. Associations of PON1 and genetic ancestry with obesity in early childhood. PLoS One. 2013;8:e62565.

Ruperez AI, Lopez-Guarnido O, Gil F, Olza J, Gil-Campos M, et al. Paraoxonase 1 activities and genetic variation in childhood obesity. Br J Nutr. 2013;110:1639–47.

Krzystek-Korpacka M, Patryn E, Hotowy K, Czapinska E, Majda J, et al. Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: association with obesity-related inflammation and oxidative stress. Adv Clin Exp Med. 2013;22:229–36.

Zaki ME, El-Bassyouni H, Kamal S, El-Gammal M, Youness E. Association of serum paraoxonase enzyme activity and oxidative stress markers with dyslipidemia in obese adolescents. Indian J Endocrinol Metab. 2014;18:340–4.

Garcés C, López-Simón L, Rubio R, Benavente M, Cano B, et al. Análisis de la actividad paraoxonasa (PON1) y de los polimorfismos PON1 192 y PON1 55 en la población prepuberal del Estudio Cuatro Provincias*. Clínica e investigación en arteriosclerosis. 2007;19:287–92.

Gonzalez V, Huen K, Venkat S, Pratt K, Xiang P, et al. Cholinesterase and paraoxonase (PON1) enzyme activities in Mexican-American mothers and children from an agricultural community. J Expo Sci Environ Epidemiol. 2012;22:641–8.

Eren E, Abuhandan M, Solmaz A, Taskin A. Serum paraoxonase/arylesterase activity and oxidative stress status in children with metabolic syndrome. J Clin Res Pediatr Endocrinol. 2014;6:163–8.

Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Fontana L, et al. Association between serum paraoxonase (PON1) gene promoter T(−107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol. 2004;39:1089–94.

Lou-Bonafonte JM, Gabás-Rivera C, Navarro MA, et al. PON1 and Mediterranean diet. Nutrients. 2015;7:4068–92.

Thông tin
Thông tin xuất bản

Nutrire

Thông tin tác giả